Zoetis (ZTS) Stock Plummets 20% Following Disappointing Q1 Results and Guidance Cut

Key Takeaways

• Zoetis shares plunged 20% to $88.94 Thursday, registering the weakest S&P 500 performance of the day
• First-quarter earnings of $1.53 per share fell short of the $1.60 Street forecast; sales of $2.26B trailed the $2.3B expectation
• Full-year EPS outlook reduced to $6.85–$7.00 from the previous $7.00–$7.10 range
• Management highlighted rising consumer cost consciousness and declining veterinary appointments as major challenges
• Stifel research indicates underlying performance is weaker than headline numbers suggest after accounting for a $100M timing benefit

Zoetis (ZTS) shares collapsed 20% to $88.94 Thursday, marking the company as the day’s worst performer among S&P 500 constituents. Data from Dow Jones Market shows the stock heading toward its weakest closing price in more than seven years, with year-to-date losses now reaching 29%.

Zoetis Inc., ZTS

The dramatic selloff followed the animal healthcare company’s first-quarter performance that disappointed across key financial metrics.

The company posted earnings of $1.53 per share, representing growth from the prior year’s $1.48 but falling short of the $1.60 Street consensus. Sales increased 3% from the year-ago period to reach $2.26 billion, missing the analyst forecast of $2.3 billion compiled by FactSet.

Chief Executive Kristin Peck acknowledged the quarter unfolded amid more challenging conditions than anticipated. Consumer reluctance to spend on pet care drove a reduction in veterinary appointments and dampened appetite for higher-priced offerings.

Domestic sales declined approximately 8% year-over-year to $1.1 billion. The companion animal category in the United States experienced an 11% drop, pressured by weakening consumer demand and intensified competitive dynamics.

Overseas Operations Provide Partial Offset

International operations delivered 17% year-over-year growth to reach $1.1 billion, supported by a 10% increase in companion animal product revenue. The parasiticides product line contributed significantly to this expansion.

Neverthably, this international figure contained approximately $100 million in revenue accelerated from a fiscal calendar adjustment. The company removed a one-month reporting delay for international subsidiaries, creating a one-time boost to first-quarter overseas results that cannot be sustained.

Wall Street Flags Underlying Weakness

Stifel analyst Jonathan Block and colleagues argued the first-quarter performance is actually “worse than it seems.” After adjusting for the $100 million realignment benefit, core operational revenue expansion fell materially below Street expectations.

Block’s research highlighted “notable weakness” in the pet care division as especially troubling.

In response, Zoetis reduced its full-year 2026 projections. The company now forecasts adjusted earnings per share of $6.85 to $7.00, down from the earlier $7.00 to $7.10 range. Analyst consensus had been centered at $7.03.

Full-year revenue projections were similarly trimmed to $9.68 billion to $9.96 billion, compared to the previous guidance of $9.825 billion to $10.025 billion. Wall Street estimates had clustered around $9.89 billion.

Peck stated the organization is implementing “decisive action to sharpen commercial execution, unlock revenue, and continue to drive disciplined cost management.”

The stock’s 20% single-session decline leaves ZTS trading at price levels last witnessed in early 2019.

Adjusted earnings per share of $1.53 represented approximately 9% annual growth, yet still came up $0.09 short of consensus projections.

Thursday’s price action brings the year-to-date decline to 29%, marking a difficult period for an equity previously regarded as a reliable growth story in the healthcare sector.

The post Zoetis (ZTS) Stock Plummets 20% Following Disappointing Q1 Results and Guidance Cut appeared first on Blockonomi.